Dysport (abobotulinumtoxinA) / Ipsen - LARVOL DELTA

Factors influencing the long-term maintenance of spasticity neurotoxin treatment. (PubMed, J Neurol Sci) - "Results suggest spasticity patients are likely to continue treatment if they are properly educated on BoNT therapy, experience improvement in spasms and mobility, and have a strong physician-patient relationship. These findings highlight the importance of effective physician-patient relationships and proper education on BoNT therapy."

Journal • Cardiovascular • Cerebral Palsy • CNS Disorders • Movement Disorders • Pain • Vascular Neurology

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis (clinicaltrials.gov) - P4 | N=90 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date

Botulinum toxin A for chronic neurovascular and myofascial facial pain: a comprehensive case report. (PubMed, Quintessence Int) - "We present the successful use of botulinum toxin type A (BoNT-A; Dysport®) in treating this patient...However, mild residual myofascial discomfort persisted. BoTN-A administration has the advantage of providing periodic rather than daily prophylactic treatment, the latter utilized by the present conventional method."

Journal • CNS Disorders • Immunology • Migraine • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Pain

Hypersensitivity Reactions Associated With Aesthetic Botulinum Toxin A Injections: A Case Series. (PubMed, Cureus) - "In the first case, a 44-year-old woman developed severe angioedema after resuming abobotulinumtoxinA injections following a 12-month pause. Subsequent intradermal tests with onabotulinumtoxinA and incobotulinumtoxinA produced localized reactions, suggesting hypersensitivity to a shared component across formulations, possibly the 150 kDa BoNT/A neurotoxin itself. In the second case, a 38-year-old woman experienced delayed erythema and swelling after letibotulinumtoxinA treatment but tolerated subsequent incobotulinumtoxinA injections, suggesting possible reactivity to complexing proteins or other non-core components rather than the neurotoxin. In the third case, a 50-year-old woman developed systemic symptoms and localized swelling after prabotulinumtoxinA administration, consistent with a delayed-type hypersensitivity reaction...Overall, this case series underscores the importance of clinical vigilance, appropriate patient selection, and awareness of rare but meaningful..."

Journal • Aesthetic Medicine • Cardiovascular • Dermatology • Immunology

Iatrogenic Botulism Following Botulinum Toxin Injection in a Child With Cerebral Palsy: A Case Report. (PubMed, J Child Neurol) - "Although regarded as safe, rare but severe systemic complications, such as iatrogenic botulism, may arise.Case PresentationWe present the case of an 8-year-old boy with cerebral palsy who experienced global muscle weakness, bilateral ptosis, dysphagia, and respiratory distress after botulinum toxin A (Dysport)...Sequential clinical photos depict the progression of the sickness and subsequent recovery, which led to progressive improvement.ConclusionIatrogenic botulism must be contemplated in individuals exhibiting new-onset bulbar or respiratory symptoms after botulinum toxin injection. Timely identification and prompt commencement of antitoxin treatment are essential for positive outcomes."

Journal • Cerebral Palsy • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Pediatrics

Computational Model-Informed Comparative Evaluation of Botulinum Toxin A Formulations: A 20-Year Simulation of Onset, Diffusion, Duration, and Immunogenicity. (PubMed, Toxicon) - "LetibotulinumtoxinA and PrabotulinumtoxinA predicted the most balanced profiles, combining high efficacy (mean peak strain reduction 72% and 68%, respectively), rapid onset (2.7-3.1 days), and minimal predicted neutralizing antibody incidence over 20 years (0.4-0.6%). DaxibotulinumtoxinA showed the longest modelled duration of effect (median 142 days), whereas AbobotulinumtoxinA and Relatox exhibited broader diffusion and higher immunogenicity risk...These simulations align closely with available empirical data and suggest that formulation-specific differences in protein structure, diffusion behaviour, and antigenicity may contribute to observed clinical variability. Model-informed comparative analysis can complement real-world and prospective studies to optimize product selection and dosing strategies in aesthetic and therapeutic applications."

Clinical • Journal

DIRECTION: A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. (clinicaltrials.gov) - P4 | N=464 | Completed | Sponsor: Ipsen | Active, not recruiting ➔ Completed

Trial completion • Movement Disorders

E-BEOND: A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults (clinicaltrials.gov) - P3 | N=714 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine • Pain

C-BEOND: A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults (clinicaltrials.gov) - P3 | N=720 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Migraine • Pain

Botulinum Toxin Treatment in Hereditary Spastic Paraplegia-A Comprehensive Review and Update. (PubMed, Toxins (Basel)) - "The injected toxin in the open-label studies was botulinumtoxin-A (Botox or Dysport or Xeomin), whereas in the blinded study, the investigators used Prosigne. The novelty of this review is that it represents a comprehensive and critical literature review on this subject, with no other studies of this kind published previously. It also includes data not present in previous reviews of this subject."

Journal • Review • Genetic Disorders • Movement Disorders • Urology

Dysport: Data readout from P3 C-BEOND trial (NCT06047444) for chronic migraine in 2026 (Ipsen) - Q3 2025 Results: Data readout from P3 E-BEOND trial (NCT06047457) for episodic migraine in 2026

P3 data • Migraine

Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A (clinicaltrials.gov) - P4 | N=3 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed

Trial completion

LIFE-THREATENING GENERALIZED MUSCLE WEAKNESS DEVELOPING AFTER INTRAVESICAL BOTULINUM TOXIN APPLICATION IN A CASE WITH NEUROGENIC BLADDER (ESPN 2025) - " Case: A 6-year-old girl who underwent surgery for meningomyocele, was on tolterodine for neurogenic bladder, and had a clean intermittent catheter, and showed bilateral grade 5 vesicoureteral reflux (VUR) taken for recurrent urinary tract infection. Subureteric transurethral injection (STING) and intravesical 30 units/kilogram abobotulinumtoxinA were applied... BTX prevents the fusion of neurosecretory vesicles at presynaptic nerve endings and the release of acetylcholine. It can be applied cystoscopically to the detrusor muscles to reduce intravesical pressure in the storage or to the sphincters to facilitate voiding in detrusorsphincter dyssynergia. Side effects occur when the toxin passes into the bloodstream and affects neuromuscular junctions in separate regions or through retrograde axonal transport to spinal motor neurons."

Clinical • Ataxia • Infectious Disease • Nephrology • Otorhinolaryngology • Pediatrics • Respiratory Diseases • STING

Budget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand. (PubMed, Clinicoecon Outcomes Res) - "This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A's inclusion in Thailand's National List of Essential Medicine."

HEOR • Journal • CNS Disorders

Use of Botulinum Toxin Application in the Inferior Oblique Capitis Muscle Under Tomographic Guidance in Cervical Dystonia Report of Two Cases (MDS Congress 2025) - "Background: The first case involves a 23-year-old patient with a psychiatric condition and a history of receiving risperidone...150 units of "Dysport" were applied to this muscle under tomographic guidance (Siemens brand, 64 slices), with local anesthesia (2% lidocaine) using a Spinocath. The analysis of cervical dystonia cases using the Col/Cap concept and the subsequent application of botulinum toxin to frequently involved deep muscles using tomographic guidance results in a significant improvement in treatment outcomes."

Clinical • CNS Disorders • Dystonia • Movement Disorders • Psychiatry

Hypersensitivity Reaction to Abobotulinumtoxin: A Case Report (MDS Congress 2025) - "Objective: To report a case of hypersensitivity reaction to abobotulinumtoxinA injections for spasticity in a patient who did not have hypersensitivity to onabotulinumtoxinA and raise awareness regarding potential unique adverse events among toxin types. While hypersensitivity reactions to BTX can occur, the reasons for skin rash remain largely unknown and may differ between the formulations. Providers should be aware of possible idiosyncratic and serious systemic reactions that may necessitate changing formulations of BTX. [Picture 2] [Picture 1]"

Case report • Clinical • Cerebral Palsy • CNS Disorders • Movement Disorders

BOTULINUM TOXIN IN PAIN RELATED POST STROKE UPPER LIMB SPASTICITY: A META-ANALYSIS ON EARLY AND LATE INJECTIONS (WCN 2025) - "The search included studies from January 2000 until January 2024. Twelve RCTs were analyzed wherein 8 used abobotulinumtoxinA, 2 used onabotulinumtoxinA, 1 used Neu-BoNT/A and 1 used incobotulinumtoxinA. Based on the pooled data from the multiple studies, there is no significant difference in the scores measuring pPSS between patients who received early BoNT injections and those who received placebo. Based on the pooled data from the multiple studies, there is no significant difference in the scores measuring pPSS between patients who received early BoNT injections and those who received placebo. This finding suggests that within the early treatment period, BoNT may not be more effective than a placebo in reducing pPSS. However, it is important to note that the data for early BoNT injections is still limited indicating that more research is needed to draw definitive conclusions [z= 1.08 (p= 0.28)]."

Retrospective data • CNS Disorders • Movement Disorders • Pain

Does preconditioning with serial casting prior to abobotulinumtoxinA injection improve outcomes in the rehabilitation of post-stroke wrist and finger flexor spasticity? (PubMed, J Neural Transm (Vienna)) - "In the BoNT-A group, a recurrence of muscle stiffness was observed at week 6. Serial casting prior to BoNT-A was associated with a trend toward more sustained reduction of spasticity, but superiority over BoNT-A alone was not statistically confirmed."

Journal • Cardiovascular • Movement Disorders • Myositis • Pain

LANTIC: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (clinicaltrials.gov) - P1/2 | N=727 | Recruiting | Sponsor: Ipsen | Trial primary completion date: Mar 2026 ➔ Aug 2026

Trial primary completion date

Evaluation of the diffusion characteristics of LetibotulinumtoxinA in comparison to Ona- and AbobotulinumtoxinA in a double-blind, randomized split-face study (EADV 2025) - "Therefore, the diffusion characteristics of LetibotulinumtoxinA (Leti-BoNTA), the market leader in South Korea, was compared with OnabotulinumtoxinA (Ona-BoNTA) and AbobotulinumtoxinA (Abo-BoNTA) in a randomized, double-blind, intra- individual split-face comparison. Leti-BoNTA exhibits precise and predictable diffusion while achieving the same clinical efficacy as Ona- and Abo- BoNTA4. Due to the significant differences in diffusion characteristics, treatment protocols should take product- specific behaviour into account, especially when changing formulations. Selection of the appropriate formulation is critical, as diffusion properties can influence therapeutic outcomes."

Clinical • Aesthetic Medicine • Dermatology

The effect of a formulation containing Subderma-Complex™ and neuromuscular modulating peptides on the sustainability of Botulinum Toxin A (BTX-A) effect. (EADV 2025) - "V1 – Screening; V2 – Start: BTX-A (Dysport) injected; creams/serum applied daily. The formulation containing Subderma-Complex™ and neuromuscular modulating peptides is safe and is capable of sustaining the Botox effect. A limitation of the study is the absence of a control arm testing the formulation without the proprietary complex, which prevents isolation of the complex's specific contribution to the observed effect."

Contact Dermatitis • Dermatitis • Dermatology • Immunology

Ultrasound Evaluation of Botulinum Toxin Treatment for Hidradenitis suppurativa: An Original Study (EADV 2025) - "Regardless of the location of skin lesions, a dosage of 100-125 Speywood Units BTX-A (Azzalure, Galderma®) per area was used... The majority of patients presented satisfactory results after treatment with botulinum toxin. This highlights the need to conduct multicenter randomized clinical trials that would assess the effectiveness of botulinum toxin as a treatment of patients suffering from hidradenitis suppurativa."

Dermatology • Hidradenitis Suppurativa • Immunology

A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A. (PubMed, Dermatol Ther (Heidelb)) - "Intradermal injection of BoNT/A appears to elicit a stronger immunogenic response than intramuscular administration, although antibody levels did not reach clinically significant thresholds. These findings underscore the importance of injection technique and interval planning to mitigate immunogenicity. Given the widespread use of intradermal techniques in aesthetic practice, this study provides important clinical insight into optimizing BoNT/A administration."

Journal

CARBUR: CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity (clinicaltrials.gov) - P=N/A | N=113 | Recruiting | Sponsor: Ipsen | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Movement Disorders

In Silico Multiscale Computational Modelling of Botulinum toxin A Diffusion for Glabellar Wrinkle Treatment: Optimizing Injection Volumes across formulations. (PubMed, Toxicon) - "Simulations encompassed five formulations- AbobotulinumtoxinA (ABO), DaxibotulinumtoxinA (DAXI), IncobotulinumtoxinA (INCO), OnabotulinumtoxinA (ONA), and PrabotulinumtoxinA (PRABO)-across injection volumes from 0.025 to 0.1 mL, at fixed toxin unit dosing, within anatomically realistic glabellar meshes (n=10,000 synthetic patient variants)...This study provides the first in-silico quantitative, multiscale evidence that reducing BoNT/A reconstitution volume to ≤0.045 mL/site significantly enhances target localization while minimizing off-target effects. Contrary to prevailing clinical heuristics, dilution amplifies mechanical spread and immune clearance risk."

Journal